Markets:

Overview

News

Currencies

International

Treasuries

ResMed Inc. Common Stock (NY:RMD)

241.35 +14.27 (+6.29%)

Delayed Quote Updated: 1:09 PM EST, Nov 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ResMed Inc. Common Stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

21 22 Next >

Uncovering Dividend Opportunities with NYSE:RMD. ↗

February 12, 2024

Why RESMED INC (NYSE:RMD) provides a good dividend, while having solid fundamentals.

Via Chartmill

MatrixCare Earns Three 2024 Best in KLAS Awards

February 07, 2024

MatrixCare has been named a market leader by KLAS Research for its Home Health EHR in three Categories: Home Health – Independent – Large, Home Health – Independent – Small, and Hospice – Independent

From MatrixCare

Via GlobeNewswire

Here's How Much You Would Have Made Owning ResMed Stock In The Last 15 Years ↗

February 01, 2024

Via Benzinga

Cracking The Code: Understanding Analyst Reviews For ResMed ↗

January 25, 2024

Via Benzinga

Why ResMed Stock Is Jumping Today ↗

January 25, 2024

The medical device maker beat expectations with its latest quarterly results.

Via The Motley Fool

Recap: ResMed Q2 Earnings ↗

January 24, 2024

Via Benzinga

ResMed's Earnings: A Preview ↗

January 23, 2024

Via Benzinga

Why NYSE:RMD provides a good dividend, while having solid fundamentals. ↗

January 17, 2024

Exploring RESMED INC (NYSE:RMD)'s dividend characteristics.

Via Chartmill

ResMed Flexes Its Operating Muscle, Sends Shares Flying Above Their 200-Day Line ↗

January 25, 2024

ResMed reported better-than-expected sales and adjusted earnings.

Via Investor's Business Daily

AT&T To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday ↗

January 25, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024

January 24, 2024

From ResMed Inc.

Via GlobeNewswire

3 Stocks to Buy to Benefit From the Booming Sleep Industry ↗

January 23, 2024

It’s not easy to find sleep stocks to buy despite the fact the industry is booming these days from society's lack of rest and relaxation.

Via InvestorPlace

If You Invested $100 In This Stock 15 Years Ago, You Would Have $900 Today ↗

January 10, 2024

Via Benzinga

Demystifying ResMed: Insights From 5 Analyst Reviews ↗

January 09, 2024

Via Benzinga

Uncovering Dividend Opportunities with NYSE:RMD. ↗

December 26, 2023

Why RESMED INC (NYSE:RMD) qualifies as a good dividend investing stock.

Via Chartmill

$1000 Invested In ResMed 15 Years Ago Would Be Worth This Much Today ↗

December 25, 2023

Via Benzinga

Earnings Scheduled For January 24, 2024 ↗

January 24, 2024

Companies Reporting Before The Bell • Freeport-McMoRan (NYSE:FCX) is estimated to report quarterly earnings at $0.22 per share on revenue of $5.86 billion.

Via Benzinga

(RMD) - Analyzing ResMed's Short Interest ↗

December 22, 2023

Via Benzinga

If You Invested $1000 In This Stock 20 Years Ago, You Would Have $17,000 Today ↗

December 14, 2023

Via Benzinga

Why NYSE:RMD qualifies as a good dividend investing stock. ↗

November 30, 2023

Is RESMED INC (NYSE:RMD) a Good Fit for Dividend Investing?

Via Chartmill

FDA Identifies ResMed's Recall Of Certain Ventilator Device Masks With Magnets As Most Serious ↗

January 12, 2024

ResMed (NYSE: RMD) recalls certain respiratory masks with magnets due to potential interference with medical devices. FDA Class I recall.

Via Benzinga

Topics Product Recall

HCA Healthcare Rallies: Weight-loss drugs really a big threat?

January 08, 2024

HCA Healthcare rebounds amid concerns about weight-loss drugs' impact. The healthcare giant's revenue growth hints at resilience despite sector challenges.

Via MarketBeat

Topics ETFs

Top Picks 2024: ResMed ↗

January 07, 2024

ResMed is the market leader in continuous positive airway pressure machines. ResMed has enjoyed a steadily growing market throughout its history, and investors have often paid sky-high valuations for...

Via Talk Markets

ResMed to Report Second Quarter Fiscal 2024 Earnings on January 24, 2024

January 03, 2024

From ResMed Inc.

Via GlobeNewswire

ResMed Announces Participation in the 42nd Annual J.P. Morgan Healthcare Conference

December 27, 2023

From ResMed Inc.

Via GlobeNewswire

ResMed Notifies Customers About Updated Instructions and Labeling for Masks with Magnets Due to Potential Interference with Certain Medical Devices

December 20, 2023

ResMed’s masks with magnets are safe when used in accordance with the updated Instructions for Use

From ResMed Inc.

Via GlobeNewswire

ResMed Secures Significant Victory in Patent Fight Against New York University

December 11, 2023

From ResMed Inc.

Via GlobeNewswire

Study Estimates a 23% Increase in COPD by 2050, Representing 600 Million Patients Globally

December 07, 2023

From ResMed Inc.

Via GlobeNewswire

Senator's Bearish Tesla Bet Under Scrutiny As He Buys Put Options Ahead Of Elon Musk-Led Company's Q3 Results That Set Stock Slide In Motion ↗

November 17, 2023

Sen. Tommy Tuberville bought 3 tranches of put options to sell Tesla shares at $190 a day ahead of Q3 results that set in motion a stock slump.

Via Benzinga

ResMed Adopts New Operating Model to Accelerate Long-term Growth

November 09, 2023

From ResMed Inc.

Via GlobeNewswire

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.